SOURCE: Bio-Rad Laboratories

Bio-Rad Laboratories

February 08, 2016 16:30 ET

Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer

HERCULES, CA and FORT COLLINS, CO--(Marketwired - Feb 8, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) and Propel Labs today announced that Bio-Rad has acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year.

Flow cytometry is a technique used for identifying and sorting cells and their components. The flow cytometry platform that Bio-Rad is acquiring will support a variety of applications including immunology, phenotypic monitoring, cell signaling, and stem cell research. This innovative and proprietary technology will offer researchers greater confidence in results along with convenience that is unmatched by other available systems.  

"We welcome the opportunity to expand our relationship with Propel Labs," said Shannon Hall, Bio-Rad President, Life Science Group. "The new instrument will complement our S3e Cell Sorter. When these instruments are combined with our antibody portfolio, Bio-Rad will offer researchers an unparalleled combination of ease and technology enabling greater insights into cellular mechanisms."

"This exciting new agreement builds on our already successful partnership with Bio-Rad," said Tidhar Sadeh, CEO of Propel Labs. "We are pleased to support Bio-Rad as it introduces an instrument that we believe will have a great impact in the area of cancer research." 

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,600 people worldwide and had revenues exceeding $2.1 billion in 2014. For more information, please visit www.bio-rad.com.

About Propel Labs
Propel Labs is a privately held biotechnology instrumentation company headquartered in Fort Collins, Colorado, USA. Propel's experience and knowledge enable the design of next generation bio-instrumentation tools. The company focuses on the customer by quickly delivering innovative products and enhancing their research to advance patient care. For more information, please visit www.propel-labs.com.

Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, problems we may encounter with our supply chain and product quality issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Contact Information

  • Press Contacts:
    Bio-Rad Laboratories, Inc.
    Tina Cuccia
    Corporate Communications
    510-724-7000
    Email Contact

    Propel Labs
    Tidar Sadeh
    CEO
    970-295-4570
    Email Contact